A plain-language guide

epidermolysis bullosa

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Growing map · 35 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. epidermolysis bullosa is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's epidermolysis bullosa?

Epidermolysis bullosa (EB) is not one disease but a family of rare inherited disorders in which the skin and other epithelial surfaces are mechanically fragile, so minor friction or trauma causes blistering and wounds. EB is divided into four main types by the level at which the skin splits: simplex (within the outer epidermis), junctional (in the lamina lucida), dystrophic (below the lamina densa), and Kindler. Severity ranges from localized blistering to life-limiting multisystem disease; chronic wounds in severe forms carry a long-term risk of skin cancer. This entry treats EB as an umbrella and confirms COL7A1, the gene behind the dystrophic form, as its principal molecular driver.

Also indexed asORPHA:79361
Features mapped13
Treatments mapped6
Published sources17
Last reviewed2026-08-04

Signs and symptoms

Atrophic scars

In the dystrophic form, repeated blistering heals with scarring; over time this scarring can fuse fingers and limit movement, and it accompanies involvement beyond the skin.

Limited evidenceSource: PMID:38085193
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:38724041, OMIM:226700
Notesplain_language confirmed from PMID:38724041 via curation 2026-06-14. | regrounded primary OMIM:226700 -> PMID:38085193 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Autosomal dominant inheritance

In dystrophic epidermolysis bullosa, the kind of change in the COL7A1 gene tends to track with how it is inherited: missense changes are linked with the dominant form, which can be passed on from one affected parent.

Limited evidenceSource: PMID:39905456
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:131800
Notesplain_language confirmed from PMID:39905456 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:131800 -> PMID:39905456 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Abnormal blistering of the skin

The defining feature is skin fragility: blisters and open wounds form in response to minor friction or trauma that would not harm normal skin.

Limited evidenceSource: PMID:32973163
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40908727, OMIM:226700
Notesplain_language confirmed from PMID:40908727 via curation 2026-06-14. | regrounded primary OMIM:226700 -> PMID:32973163 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Nail dysplasia

Some forms of epidermolysis bullosa affect the nails, so deformed, thickened, or lost nails can be a sign of the condition alongside the skin fragility.

Limited evidenceSource: PMID:27931749
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:226700
Notesplain_language confirmed from PMID:27931749 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:226700 -> PMID:27931749 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Nail dystrophy

Nail changes (thickened, deformed, or lost nails) are common, sometimes the most visible sign in milder, localized disease.

Limited evidenceSource: PMID:33849616
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41277647, OMIM:226700
Notesplain_language confirmed from PMID:41277647 via curation 2026-06-14. | regrounded primary OMIM:226700 -> PMID:33849616 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Milia

As blistered skin heals in dystrophic epidermolysis bullosa, tiny firm white bumps called milia often appear where the skin repaired itself. They are small cysts of trapped keratin and are a common, harmless sign that scarring has occurred.

Limited evidenceSource: PMID:33849616
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:34543471, OMIM:226700
Notesplain_language confirmed from PMID:34543471 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:226700 -> PMID:33849616 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Syndactyly

In dystrophic epidermolysis bullosa, repeated blistering and scarring can fuse the webspaces between the fingers and toes (pseudosyndactyly), which over time can draw the hand into a mitten-like shape.

Limited evidenceSource: PMID:33849616
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:38085193, OMIM:226700
Notesplain_language confirmed from PMID:38085193 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:226700 -> PMID:33849616 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Failure to thrive

In the generalized severe forms of epidermolysis bullosa, widespread, long-lasting wounds and involvement of the moist body linings can drain the body's resources, and malnutrition is one of the complications that can follow.

Limited evidenceSource: PMID:40091088
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:27931749, OMIM:226700
Notesplain_language confirmed from PMID:27931749 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:226700 -> PMID:40091088 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Autosomal recessive inheritance

In recessive dystrophic epidermolysis bullosa, the condition follows a recessive pattern: a change in a single gene drives skin blistering that ranges widely, from fragility limited to one area to complications affecting the whole body.

Limited evidenceSource: PMID:39905456
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41637086, OMIM:226700
Notesplain_language confirmed from PMID:41637086 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:226700 -> PMID:39905456 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Pyloric stenosis

A few severe subtypes of epidermolysis bullosa are present from birth together with a blockage where the stomach empties into the intestine (pyloric atresia). A baby with this combination cannot pass feeds through and needs surgery early in life; it is a clue that points toward specific laminin- or integrin-related forms of the disease.

Limited evidenceSource: PMID:27931749
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41948702, OMIM:226700
Notesplain_language confirmed from PMID:41948702 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:226700 -> PMID:27931749 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Skin blistering

In epidermolysis bullosa, the skin is mechanically fragile, and repeated, widespread blistering is a characteristic feature of the condition.

Limited evidenceSource: PMID:40908727
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:36689495
Notesplain_language confirmed from PMID:40908727 via curation 2026-06-18 [carrie (curation)]. plain_language confirmed from PMID:36689495 via curation 2026-06-25 [claude-draft].
Last reviewed2026-06-25

Squamous cell carcinoma

In severe epidermolysis bullosa, skin that blisters and heals over and over can develop chronic, non-healing wounds. Over years, these wounds can give rise to an aggressive skin cancer called squamous cell carcinoma, which ranks among the leading reasons for early death in the most severe subtypes. Regular skin checks of long-standing wounds matter for this reason.

Limited evidenceSource: PMID:36689495
Evidence ratingweak
Study designliterature_review
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:36689495 via curation 2026-06-18 [carrie (curation)]. plain_language revised from PMID:36689495 via curation 2026-06-18 [carrie (curation)].
Last reviewed2026-06-18

Mucosal involvement

Epidermolysis bullosa can affect not only fragile skin but also the moist linings of the body (mucous membranes), and in generalized severe forms this mucosal involvement can contribute to systemic complications.

Limited evidenceSource: PMID:41948702
Evidence ratingweak
Study designcase_report
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:27931749
Notesplain_language confirmed from PMID:41948702 via curation 2026-06-18 [carrie (curation)]. plain_language confirmed from PMID:27931749 via curation 2026-06-25 [claude-draft].
Last reviewed2026-06-25

How it is diagnosed

epidermolysis bullosa

Diagnosed using: immunofluorescence mapping of skin biopsy.

Limited evidenceSource: PMID:27931749
The source text this rests on
“Clinically suspected diagnosis is confirmed by immunohistochemical examination of a skin biopsy at specialized centres in order to determine the level of cleavage and the deficient…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:27931749 via curation 2026-06-25
Last reviewed2026-06-25

epidermolysis bullosa

Diagnosed using: targeted next-generation sequencing gene panel.

Limited evidenceSource: PMID:29242947
The source text this rests on
“…the molecular pathology was completely elucidated in 90% of cases by the targeted NGS multi-gene…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:29242947 via curation 2026-06-25
Last reviewed2026-06-25

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

wound care and dressings

A central goal of care in epidermolysis bullosa is preventing and treating skin lesions using specific non-adherent dressings, alongside preventing, detecting and treating complications.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:38170434
The source text this rests on
“Dressing changes and wound care are central to the management of EB.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:27931749
Notesconfirmed from PMID:38170434 via curation 2026-06-14
Last reviewed2026-06-14

oleogel-S10 (birch triterpenes)

Oleogel-S10 (birch-bark triterpenes, brand name Filsuvez) is a topical gel applied to wounds. In a phase III trial it sped wound closure in dystrophic, junctional, and Kindler EB and was the first therapy to show accelerated wound healing in EB.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:36689495
The source text this rests on
“Oleogel-S10 is the first therapy to demonstrate accelerated wound healing in EB.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:36689495 via curation 2026-06-14
Last reviewed2026-06-14

beremagene geperpavec

Beremagene geperpavec (Vyjuvek) is a topical gene therapy: a herpes-simplex viral vector delivers working copies of COL7A1 to wounds, restoring type VII collagen in dystrophic EB. Approved in the US in 2023, it was the first approved treatment for dystrophic EB and is applied to wounds and re-dosed.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:37432558
The source text this rests on
“In May 2023, beremagene geperpavec received its first approval in the US for the treatment of wounds in patients ≥ 6 months of age with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 gene.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:37432558 via curation 2026-06-14
Last reviewed2026-06-14

iron supplementation and anemia management

Anemia is a common complication of severe epidermolysis bullosa, and managing it is part of care: dietary measures for everyone, iron taken by mouth for mild anemia, and iron given by infusion for moderate to severe anemia.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:36823529
The source text this rests on
“Dietary measures should be offered as part of management of anemia in all EB patients, oral iron supplementation should be used for mild anemia; while iron infusion is reserved for moderate to severe…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:36823529 via curation 2026-06-25
Last reviewed2026-06-25

surgical pseudosyndactyly release

When scarring fuses the fingers in dystrophic epidermolysis bullosa, surgery can separate the joined webspaces to free the hand; because the scarring tends to return, this release is often repeated over time.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:38085193
The source text this rests on
“…traditional and current treatment for DEB is largely supportive with wound care and iterative surgical pseudosyndactyly…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:38085193 via curation 2026-06-25
Last reviewed2026-06-25

multidisciplinary supportive care

Because there is no cure yet, care for epidermolysis bullosa is shared across a team and aimed at reducing new blisters, caring for wounds, easing symptoms, and watching for complications, including squamous cell carcinoma, a skin cancer that is the leading cause of death in the condition.

Used to help with: epidermolysis bullosa.

Limited evidenceSource: PMID:32973163
The source text this rests on
“…multidisciplinary care is targeted towards minimizing the risk of blister formation, wound care, symptom relief and specific complications, the most feared of which - and also the leading cause of mortality - is squamous cell…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:32973163 via curation 2026-06-25
Last reviewed2026-06-25

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 17 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:131750 · Orphanet/HPO annotations for Epidermolysis bullosa dystrophica, autosomal dominant
ORPHA:79361 · Orphanet/HPO annotations for epidermolysis bullosa
PMID:27931749 · [Hereditary epidermolysis bullosa: French national guidelines (PNDS) for diagnosis and treatment].
PMID:29242947 · The Position of Targeted Next-generation Sequencing in Epidermolysis Bullosa Diagnosis.
PMID:32973163 · Epidermolysis bullosa.
PMID:33849616 · A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
PMID:36689495 · Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized
PMID:36823529 · Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa.
PMID:37432558 · Beremagene Geperpavec: First Approval.
PMID:38085193 · Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts.
PMID:38170434 · Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years.
PMID:38724041 · Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermol
PMID:39905456 · A pathogenic COL7A1 variant highlights semi-dominant inheritance in dystrophic epidermolysis bullosa.
PMID:40091088 · Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus.
PMID:40667654 · Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Su
PMID:40908727 · Epidermolysis bullosa skin fragility (literature)
PMID:41948702 · Epidermolysis bullosa mucosal involvement (literature)

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.